– USA, CA – Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that David Moatazedi, Senior Vice President, US Medical Aesthetics for Allergan plc has been appointed to its board of directors. Mr. Moatazedi is the second addition to the Obalon board of directors in 2017, as Obalon continues its launch of the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intragastric balloon system for weight loss.
“Mr. Moatazedi leads an in-depth portfolio of some of the most respected brands in aesthetics that consumers want and physicians depend on,” commented Andy Rasdal, Chief Executive Officer of Obalon. “This addition to our board of directors brings a critical voice to our company and of our advisory team at an important moment in Obalon’s growth.”
Mr. Moatazedi is currently the Senior Vice President, US Medical Aesthetics for Allergan plc. In this role, Mr. Moatazedi is a member of the Allergan Commercial Leadership Team with multiple business unit responsibility, including Facial Aesthetics, Plastics and Regenerative Medicine and Skincare. Mr. Moatazedi has over seventeen years’ commercial experience managing upstream and downstream marketing, working across multiple brands with increasing responsibility. He has also led several business units as Vice President, Sales and Marketing beginning with Plastic Surgery and followed by Facial Aesthetics.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence.
For more information : http://www.obalon.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.